Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
Also Known As
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
ImmunOs Therapeutics
ImmunOs Therapeutics is a clinical-stage biotech developing novel human immunomodulatory proteins for cancer and autoimmune diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
cCAM Biotherapeutics
cCAM Biotherapeutics develops immunotherapies for cancer.
Sector
Subsector
Keywords
Location
total rounds
ITeos Therapeutics
ITeos Therapeutics is a biotechnology company specializing in tumor immunology and cancer immunotherapy.
Sector
Subsector
Keywords
Location
total rounds
total raised
OSE Immunotherapeutics
OSE Immunotherapeutics is a biotech company developing innovative treatments for cancer and inflammatory diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
M&A Details1
Transaction name
Acquired by
Ikena Oncology
announced date
Financials
Funding Rounds4
Number of Funding Rounds
Money Raised
Their latest funding was raised on 23.06.2020. Their latest investor OUP (Osage University Partners). Their latest round Corporate Round
Gilead Sciences
Gilead Sciences is a biopharmaceutical company that develops and commercializes innovative medicines.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
QB3
QB3 accelerates bioscience innovation for societal benefit as a research consortium.
Sector
Subsector
Location
count Of Investments
Vida Ventures
Vida Ventures is a life sciences company that funds biomedical innovations to improve patients' lives.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
New Enterprise Associates
NEA is a global venture capital firm that helps entrepreneurs build innovative businesses in technology and healthcare.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Sofinnova Investments
Sofinnova Investments is a venture capital firm that specializes in funding and supporting Life Science and Technology start-ups.
Sector
Subsector
Location
count Of Investments
count Of Exists
Co-Investors
Investors12
Number of lead investors
Number of investors
OUP (Osage University Partners)
Osage University Partners (OUP) is a venture capital fund that invests exclusively in startups commercializing university research.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
QB3
QB3 accelerates bioscience innovation for societal benefit as a research consortium.
Sector
Subsector
Location
count Of Investments
SV Health Investors
SV Health Investors is a leading healthcare and life sciences venture capital and growth equity firm.
Sector
Subsector
Location
count Of Investments
count Of Exists
Joshua Resnick
Josh is co-founder and chief executive officer of Ataxion, and previously served on the board of CoStim Pharmaceuticals, which was sold to Novartis in February 2014. He is also an attending physician in emergency medicine at Brigham and Women's Hospital as well as an instructor at Harvard Medical School. Prior to joining Atlas, Josh was a partner at Prism Ventures.
current job
People
Founders2
Max Krummel
Dr. Krummel is a Professor and the Robert E. Smith Endowed Chair in Experimental Pathology at UCSF. He studies mechanisms that regulate T cell response and immune function, using cutting-edge real-time imaging methods. As a graduate student, he developed expertise in the generation and use of monoclonal antibodies targeted to costimulatory and inhibitory molecules on T cells. He generated antibodies to CTLA-4, which identified an inhibitory pathway of T cell regulation and also could be used to trigger or block that pathway. This approach led to the development of human antibodies of the same type, a therapy now named ‘ipilimumab’, now FDA approved and widely used for treatment of melanoma and other cancers. Dr. Krummel’s lab now focuses on figuring out how immune systems, collections of cells in complex tissues, work. The use of fluorescent proteins and real-time imaging enable the examination of information processing by the immune system. These approaches reveal how motile immune cells ‘search’ their environment for critical information and characterize specific phagocytes in the tumor microenvironments as primary players in transmitting signals to lymphocytes and regulating disease outcome. Dr. Krummel earned his doctorate at UC Berkeley and did postdoctoral fellowships at Stanford University and the Walter and Eliza Hall Institute in Melbourne, Australia.
current job
organization founded
Max Krummel
Sachdev Sidhu
Sidhu is an expert in phage display technology and structure-based and combinatorial protein engineering. Prior to joining the University of Toronto in April 2008, he spent a decade as a principal investigator in the Department of Protein Engineering at Genentech, Inc., where he led the development of phage-displayed synthetic antibody libraries that have since proven to be a rich source of valuable reagents for basic research and potential therapeutics. His University of Toronto laboratory houses the TRAC (Toronto Recombinant Antibody Centre), an integrated laboratory with a state-of-theart, high throughput antibody research platform that can be applied to the generation of therapeutic-grade antibodies. Recently, Dr. Sidhu has launched the Centre for the Commercialization of Antibodies and Biologics (CCAB), a Government of Canada-sponsored Centre of Excellence, that functions as a bridge between academic discoveries and their industrial production and marketing.
current job
organization founded
Sachdev Sidhu
Employee Profiles22
Sayantan Mitra
Principal scientist and group leader, protein sciences
Larry Garrido
Senior director facilities operations